A Phase 3 Randomized Precision Medicine Clinical Trial Using Low-Dose Ondansetron (a 5-HT3 Antagonist) to Treat Alcohol Use Disorder
Preprint in Research Square (July 2023)
The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.
Preprint in Research Square (July 2023)
Book chapter (June 2023)
Article in Frontiers in Behavioral Neuroscience (April 2023)